Ovarian hyperstimulation syndrome

Gameto Announces Patient Experience Data Demonstrating Investigational In Vitro Maturation Solution Well Tolerated with Higher Patient Satisfaction Rates than Conventional Fertility Stimulation

Retrieved on: 
Tuesday, April 2, 2024
Disease, Biotechnology, Data analysis, Abdominal pain, Patient, IVF, COS, Female, Fertility, Manuscript, Fertilisation, Freezing, Woman, OHSS, Pain, Vomiting, IPSC, FDA, IVM, Ovarian hyperstimulation syndrome, Cell, Birth control

NEW YORK, April 2, 2024 /PRNewswire/ -- Gameto, a female-led biotechnology company with a mission to redefine women's healthcare, today announced encouraging new findings from a study evaluating how minimal controlled ovarian stimulation (COS) in combination with Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, affected patients' egg retrieval experiences when compared to conventional stimulation. The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).

Key Points: 
  • The data analysis found that women undergoing minimal hormonal stimulation for OSC-IVM reported experiencing few side effects, lower levels of pain after retrieval, and higher satisfaction levels with the shortened stimulation procedure, compared to conventional stimulation for in vitro fertilization (IVF).
  • "We are encouraged by these and previously published efficacy data which demonstrate that combining minimal hormonal stimulation with our investigational in vitro maturation solution may help women navigating fertility treatments avoid many of the common side effects associated with the conventional IVF hormone protocol.
  • Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.
  • [1],[2] In contrast, the participants in this analysis who underwent minimal ovarian stimulation cycles followed by OSC-IVM yielded no incidence of OHSS.

Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

Retrieved on: 
Monday, July 10, 2023
Health, Consumer, Women, Research, Science, Pharmaceutical, Biotechnology, Hypersensitivity, Vaginal bleeding, News, Gonadotropin, Ganirelix, Pregnancy, Anaphylaxis, Society, Ovarian hyperstimulation syndrome, Fresenius (company), American Society for Reproductive Medicine, Parent, Ovulation, LH, Woman, ART, Infertility, Multimedia, USP, Fertilisation, Luteinizing hormone, Abdominal pain, ML, Injection site reaction, Assisted reproductive technology, LaTeX, Patient, Physician, Risk, Injection, Fertility, HCG, SART, Nausea, Gonadotropin-releasing hormone, Reproductive medicine, FDA, Headache, Syringe, Pharmaceutical industry, Birth control, Organon

Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.

Key Points: 
  • Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.
  • Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes.
  • View the full release here: https://www.businesswire.com/news/home/20230710582430/en/
    Now available: Fresenius Kabi Ganirelix Acetate Injection.
  • Ganirelix Acetate Injection is the third product offering in Fresenius Kabi’s Women’s Health portfolio, which includes Chorionic Gonadotropin for Injection, USP (hCG) and Progesterone Injection, USP.

Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine

Retrieved on: 
Monday, March 13, 2023
Health, Pharmaceutical, Woman, IVF, Phase 3, Research, Contraindication, OS, ADR, Senior, Pregnancy, Maternal health, Reproductive medicine, Ferring Pharmaceuticals, GRAPE, OHSS, RCT 1, Observational study, Patient, Pregnancy rate, Congress, Frontiers in Endocrinology, PSRM, Ovarian hyperstimulation syndrome, Adverse drug reaction, Isabella Tree, Safety, Vrije Universiteit Brussel, Incidence, ICSI, Physician, Pacific Society for Reproductive Health Trust, AMH, Oocyte, Pharmaceutical industry, Birth control, Gonadotropin preparations, Endocrinology

Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia.

Key Points: 
  • Today, an oral poster of the first post-authorisation Phase 4 real-world study, PROFILE, is being presented at the 13th Congress of the Pacific Society for Reproductive Medicine (PSRM) 2023 in Australia.
  • Results highlighted that with Rekovelle, almost three-quarters (74.0%) of women had between 4-19 oocytes retrieved and 255 women (27.0%) achieved an ongoing pregnancy at 10-11 weeks after transfer.
  • Adverse drug reactions (ADRs) were monitored for all initiated OS cycles, and the number of ADRs leading to treatment and study discontinuation was low (n=4).
  • “Ferring is committed to building healthy families of every shape and size by developing innovative fertility treatments.

Fertility Drugs Global Market Report 2022: Increasing Rates of Infertility Across the Globe Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022
Health, General Health, Lists of diseases, Sale, Acquisition, Male, Ovarian hyperstimulation syndrome, Skin, Fear, Intramuscular injection, Female, Flash, Woman, Flushing, Infertility, Ferring Pharmaceuticals, Ganirelix, Headache, Ovulation, Reproduction, Pharmacy, OHSS, Route of administration, Mood Swings, COVID-19, Drug recall, CAGR, Bloating, Diarrhea, Administration, FDA, Nausea, Patient, Globe, Man, CDC, Breast, Vomiting, Korea Disease Control and Prevention Agency, Growth, Center, Sun Pharma, Birth control, Clomifene

The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs.

Key Points: 
  • The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs.
  • The growth of the fertility drugs market is driven by the increasing rates of infertility across the globe.
  • Hence, the rising cases of infertility across the globe is increasing the demand for fertility drugs, resulting in the growth of fertility drugs market.
  • 2) By Route of Administration: Oral; Intravenous; Subcutaneous; Intramuscular
    3) By Type Of Drug: Prescription Fertility Drugs; Over-The-Counter Fertility drugs

EMD Serono Launches New Sustainable Slim Pack for Fertility Medication

Retrieved on: 
Thursday, February 17, 2022
Carbon, Abdominal pain, Calendar, Stroke, Thrombus, Itchy, Bruise, Cyst, Hospital, Face, Epistasis, Ovarian hyperstimulation syndrome, ART, Anovulation, OHSS, Pregnancy, Merck Serono, Birth, Female, Structured Product Labeling, Neoplasm, Woman, RFF, Research, Pen, FSH, Vitamin, Skin, Life, PCOS, Heart, Diarrhea, CO2, Rash, Headache, Risk, Infection, Use, Brain, Health, Death, Weight gain, Breast, Hypothalamus, Miscarriage, Pain, Vomiting, Carbon footprint, Blood, Thrombosis, Multiple sclerosis, Asthma, Patient, Cancer, Bronchoscopic lung volume reduction (BLVR), Transport, Polycystic ovary syndrome, Efficiency, Infertility, Merck Group, Uterus, FDA, KPMG, Nausea, Multimedia, Stomach, Allergy, Pharmaceutical industry, Recycling, Birth control, Medical imaging, Beekeeping, Merck

ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.

Key Points: 
  • ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.
  • "Our new Slim Pack isan initiative we hope will drive convenience while reducing our overall carbon footprint."
  • Slim Pack will lower GONAL-f RFF* Redi-ject's global carbon footprint by 33%.
  • Plastic savings calculated using the unit weight of individual plastic tray and multiplied by the total production volume in one calendar year, once Slim Pack fully implemented across all fertility pens worldwide.

Global Ovarian Hyperstimulation Syndrome Clinical Trials Trials Research Report H2, 2021: Phase, Trial Status, End Points Status and Sponsor Type Review - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 11, 2021
Biotechnology, Medical Devices, Other Health, Health, Pharmaceutical, E7, E7 (countries), Clinical trial, Decision-making, G7, Trial, Ovarian hyperstimulation syndrome, Birth control, Pharmaceutical industry

The "Ovarian Hyperstimulation Syndrome - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ovarian Hyperstimulation Syndrome - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Ovarian Hyperstimulation Syndrome - Global Clinical Trials Review, H2, 2021" provides an overview of Ovarian Hyperstimulation Syndrome Clinical trials scenario.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    the report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    the report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Ovarian Hyperstimulation Syndrome to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Ovarian Hyperstimulation Syndrome to Women's Health Clinical Trials

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals

Retrieved on: 
Thursday, November 4, 2021
Safety, Anemia, Plasticizer, History, EUR, Commercial Operating System (COS), MCE, Multimedia, Health, GRF, ADR, Allergy, PVC, Coagulation, Blood, Transfusion medicine, Ovarian hyperstimulation syndrome, Creutzfeldt–Jakob disease, Hematology, Food, Water, Regulation of tobacco by the U.S. Food and Drug Administration, Respiratory distress syndrome, S.A, Solution, Plasmapheresis, Pharmacy, Hospital, Excipient, Red blood cell, Carbon, Dehydration, Hypersensitivity, CJD, Hypovolemia, Phthalate, Sale, Legislation, Heart failure, Patient, Heart, Plasma, Hemolysis, Anaphylaxis, Pulmonary edema, Paracentesis, Hypervolemia, NASDAQ, FDA, Electrolyte, Adult, Polyvinyl chloride, DEHP, Blood product, Medical device, Birth control

"This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."

Key Points: 
  • "This step forward will expand and differentiate Grifols' industry-leading albumin portfolio to benefit patients and bring convenient, flexible container options to our customers."
  • Sustainability was key for Grifols when developing the environmentally friendly ALBUTEIN FlexBag.
  • Both the ALBUTEIN FlexBag flexible container and protective overwrap are latex-free and do not contain polyvinyl chloride (PVC), diethylhexyl phthalate (DEHP) or other plasticizers.
  • The launch of ALBUTEIN FlexBag solidifies Grifols commitment to R+D+i, which has enabled the company to further expand its industry-leading portfolio of plasma-derived medicines for patients and healthcare professionals.